RBC Capital raised the firm’s price target on Gilead (GILD) to $95 from $92 and keeps a Sector Perform rating on the shares. The firm is updating its model based on its 2022 patient survey to gauge how perceptions of lena among high-risk individuals on/off PrEP may have changed following phase 3 data and approaching potential launch, citing high clinician engagement, lower-than-expected oral adherence, and consideration of switching among current PrEP users could all facilitate growth even with some Descovy cannibalization, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Balancing Strategic Growth and Clinical Uncertainty with a Hold Rating
- Gilead hold has limited near to medium term impact, says Morgan Stanley
- Gilead Sciences: Buy Rating Affirmed Amid Strategic Positioning and Robust HIV Pipeline
- Oppenheimer ‘not sounding the alarm just yet’ on Gilead after clinical hold
- Citi sees Gilead clinical holds as only ‘minor setback’